Structure Therapeutics Inc (GPCR)
36.46
-1.23
(-3.26%)
USD |
NASDAQ |
Nov 15, 10:00
Structure Therapeutics Free Cash Flow (Quarterly): -26.82M for June 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -26.82M |
| March 31, 2024 | -34.24M |
| December 31, 2023 | -22.88M |
| September 30, 2023 | -21.38M |
| June 30, 2023 | -17.08M |
| Date | Value |
|---|---|
| March 31, 2023 | -20.31M |
| December 31, 2022 | -12.10M |
| September 30, 2022 | -10.55M |
| June 30, 2022 | -10.04M |
| March 31, 2022 | -13.58M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-34.24M
Minimum
Mar 2024
-10.04M
Maximum
Jun 2022
-18.90M
Average
-18.70M
Median
Free Cash Flow (Quarterly) Benchmarks
| Viking Therapeutics Inc | -21.96M |
| Eli Lilly and Co | -458.90M |
| Novo Nordisk AS | 4.748B |
| Pfizer Inc | 6.063B |
| Amgen Inc | 3.314B |